At a glance
ClinicalIndex Comparison Record- ✓Verified HD mutation carriers
- ✓Irritability diagnosed by Irritability Scale with score >14
- ✓Stable concomitant medication with no changes in the last 30 days prior to inclusion
- ✕Hypersensitivity to dextromethorphan, quinine, quinidine, mefloquine, or dextromethorphan/quinidine with history of thrombocytopenia, hepatitis, bone marrow depression, or lupus-like syndrome
- ✕Active suicidality based on Columbia-Suicide Severity Rating Scale responses
- ✕Uncontrolled medical conditions such as uncontrolled arterial hypertension or diabetes mellitus
- ✕Clinically significant renal dysfunction with calculated creatinine clearance <30 ml/min or hepatic dysfunction
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease
In Brief
A Phase 3 clinical trial evaluating Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) and Placebo for Huntington Disease and Irritability. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to assess efficacy and safety of dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) in patients with irritability due to Huntington's disease.
Study Details
Timeline
Interventions
DM/Q 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.